Pharmaceutical Executive Daily: Wegovy Pill Becomes Available

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, the Wegovy Pill becomes the first available oral GLP-1 for weight management, clears a new therapy to prevent motion-induced vomiting, and Sanofi enters a new antibody discovery collaboration targeting autoimmune disease.

Novo Nordisk has announced its pill version of Wegovy is available for patients, making it the first GLP-1 pill available in the U.S. for chronic weight management. This marks a major milestone for the obesity market, offering patients a non-injectable option and potentially broadening access as demand for GLP-1 therapies continues to accelerate.

The FDA has approved Nereus for the prevention of motion-induced vomiting. The decision introduces a new option in a space that has seen limited innovation, with the therapy positioned to address both civilian and defense-related needs where motion sickness can significantly impact performance and safety.

In pipeline news, Sanofi has entered a collaboration with Earendil Labs to discover and develop novel antibodies for autoimmune diseases. The partnership expands Sanofi’s immunology portfolio and reflects continued industry investment in next-generation biologics aimed at difficult-to-treat inflammatory conditions.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.